Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2025
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
N I Cherny, S F Oosting, U Dafni, et al.
ESMO Open
|
June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
P Martin, Z Tsourti, J Ribeiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat, A Curioni-Fontecedro, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
E Felip, S Popat, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2023
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
B Kiesewetter, U Dafni, E G E de Vries, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
L Castelo-Branco, A Pellat, D Martins-Branco, et al.
ESMO Open
|
June 1, 2022
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
L Castelo-Branco, Z Tsourti, S Gennatas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S Peters, J-L Pujol, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2025
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
N I Cherny, S F Oosting, U Dafni, et al.
ESMO Open
|
June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
P Martin, Z Tsourti, J Ribeiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat, A Curioni-Fontecedro, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
E Felip, S Popat, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2023
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
B Kiesewetter, U Dafni, E G E de Vries, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
L Castelo-Branco, A Pellat, D Martins-Branco, et al.
ESMO Open
|
June 1, 2022
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
L Castelo-Branco, Z Tsourti, S Gennatas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S Peters, J-L Pujol, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 8